Radiopharmaceutical Trial Logistics in Latin America: A Sponsor’s Playbook for Isotope Supply and Shipment Risk

Radiopharmaceutical trials can deliver decisive evidence quickly—but only if the isotope and drug product arrive exactly when the protocol needs them. In Latin America, sponsors often underestimate how much logistics determines whether a nuclear medicine study stays on schedule.

This playbook explains how to plan radiopharmaceutical clinical trial logistics in Latin America: how to think about isotope supply constraints, how shipment rules affect scheduling, and what operational controls reduce risk across countries and sites.

1) Why radiopharmaceutical logistics behave differently than “regular” clinical supply

Radiopharmaceutical supply chains are shaped by physics and regulation. Short half-lives compress the delivery window, and transport is governed by dangerous-goods rules that require correct classification, packaging, labeling, and documentation. Air carriers may impose stricter acceptance policies than the baseline regulations, meaning a shipment can be rejected even if it is “technically compliant.”

For sponsors, this means two things: (1) the critical path is often the shipment acceptance process, not the manufacturing step, and (2) your protocol schedule needs built-in flexibility for shipping windows.

2) Build your “isotope availability model” before you lock the protocol calendar

Before finalizing visit schedules, sponsors should map isotope availability and constraints:

• Production modality: reactor-produced vs cyclotron-produced isotopes have different outage risks and distribution footprints.
• Lane feasibility: direct flights vs multi-leg routes; the more handoffs, the higher the probability of delay.
• Site readiness: receiving procedures, radiation safety officer availability, and hot-lab capacity.
• Redundancy: secondary suppliers and alternative lanes that can be activated quickly.

In practice, the sponsor’s goal is to convert “isotope risk” into a schedule plan: identify which visits require exact timing and where windows can be widened without compromising scientific validity.

3) Shipment acceptance: treat documentation as a quality system, not paperwork

Dangerous-goods air shipment requirements are aligned to international aviation technical instructions, but real-world acceptance depends on flawless execution: correct hazard classification, compliant packaging, correct labels/markings, and validated shipping papers. Forwarders commonly perform a regulation check and documentation validation step before a carrier will accept the booking, and carriers may refuse certain dangerous goods categories or require pre-approval.

Operational best practices include:

• Standardize templates for shipping papers and site receiving logs.
• Pre-clear with carriers and confirm acceptance policies before the shipment arrives at the warehouse.
• Run a “dry run” shipment simulation (without active product) to validate lane timing, broker actions, and site receipt workflow.
• Define handoff accountability at every step: manufacturer → forwarder → airline → customs broker → site.

These controls reduce last-minute rejections and help sponsors avoid protocol deviations caused by delayed dosing or imaging windows.

4) Latin America-specific risk: cross-border variability and limited buffer time

Latin American operations add variability because requirements and infrastructure differ across countries and even across airports. Two practical implications matter most:

• Customs and clearance variability. A lane that works smoothly in one country may be unpredictable in another unless the broker has deep experience with radioactive/dangerous goods.
• Limited buffer time. Short half-lives reduce your ability to absorb delays; redundancy becomes essential (backup flight options, backup production, and backup sites).

When designing the operational plan, sponsors should assume that a percentage of shipments will be disrupted and proactively decide what happens next: reschedule patient, switch site, switch lane, or activate an alternate supplier.

FAQ

• What is the single biggest operational mistake in radiopharmaceutical trials?
  Locking a tight protocol schedule before validating the end-to-end shipment acceptance process and lane reliability.
• How do dangerous-goods rules affect clinical trial timelines?
  They introduce additional steps—classification checks, packaging/labeling verification, documentation validation, and carrier pre-approval—that can determine whether shipments move as planned.
• How can sponsors de-risk isotope supply in Latin America?
  Build redundancy (secondary suppliers and lanes), standardize documentation, pre-clear carriers, and validate site receiving readiness with a dry run.

Bottom line: Radiopharmaceutical trials in Latin America succeed when sponsors operationalize logistics as part of the study design—aligning isotope availability, carrier acceptance, and site readiness with the protocol calendar.

Sources referenced for general dangerous-goods shipment context: The overview of IATA DGR alignment to ICAO technical instructions and common shipment acceptance steps is summarized from a freight-forwarder explainer (Dimerco) and a dangerous-goods primer noting radioactive materials as Class 7 (EV Cargo).